Operaciones Bristol-Myers Squibb Co - BMY CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.19 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.030779% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | -0.013666% | ||||||||
Horario tarifa nocturna | 22:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Bristol-Myers Squibb Co ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Cierre previo* | 72.58 |
Abrir* | 72.48 |
Cambio de 1 año* | 11.8% |
Rango del día* | 70.77 - 72.62 |
Rango de 52 semanas | 62.90-81.44 |
Volumen medio (10 días) | 7.99M |
Volumen medio (3 meses) | 180.84M |
Capitalización de mercado | 154.47B |
Ratio P/E | 23.68 |
Acciones en circulación | 2.13B |
Ingresos | 46.74B |
EPS | 3.07 |
Dividendo (Rendimiento %) | 3.13833 |
Beta | 0.42 |
Próxima fecha de resultados | Feb 2, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Feb 1, 2023 | 71.10 | -1.20 | -1.66% | 72.30 | 72.76 | 69.93 |
Jan 31, 2023 | 72.58 | 0.95 | 1.33% | 71.63 | 72.58 | 71.56 |
Jan 30, 2023 | 71.96 | -0.32 | -0.44% | 72.28 | 72.82 | 71.77 |
Jan 27, 2023 | 72.37 | -0.20 | -0.28% | 72.57 | 73.37 | 72.19 |
Jan 26, 2023 | 72.90 | 0.30 | 0.41% | 72.60 | 73.11 | 71.83 |
Jan 25, 2023 | 73.07 | 0.68 | 0.94% | 72.39 | 73.16 | 71.79 |
Jan 24, 2023 | 72.28 | -0.48 | -0.66% | 72.76 | 73.38 | 71.93 |
Jan 23, 2023 | 73.15 | -0.78 | -1.06% | 73.93 | 74.11 | 72.73 |
Jan 20, 2023 | 74.07 | 0.30 | 0.41% | 73.77 | 74.07 | 73.22 |
Jan 19, 2023 | 73.67 | 2.24 | 3.14% | 71.43 | 73.79 | 71.43 |
Jan 18, 2023 | 72.07 | 0.11 | 0.15% | 71.96 | 72.59 | 71.07 |
Jan 17, 2023 | 72.23 | -0.67 | -0.92% | 72.90 | 73.38 | 71.91 |
Jan 13, 2023 | 72.42 | 0.92 | 1.29% | 71.50 | 72.44 | 71.23 |
Jan 12, 2023 | 71.53 | 0.08 | 0.11% | 71.45 | 71.86 | 70.93 |
Jan 11, 2023 | 71.85 | 0.38 | 0.53% | 71.47 | 71.90 | 70.79 |
Jan 10, 2023 | 71.58 | 0.44 | 0.62% | 71.14 | 71.62 | 70.57 |
Jan 9, 2023 | 70.94 | -1.77 | -2.43% | 72.71 | 72.96 | 70.68 |
Jan 6, 2023 | 72.94 | 1.33 | 1.86% | 71.61 | 73.32 | 71.61 |
Jan 5, 2023 | 71.83 | 0.14 | 0.20% | 71.69 | 72.31 | 71.37 |
Jan 4, 2023 | 72.53 | 0.46 | 0.64% | 72.07 | 73.18 | 71.45 |
Bristol-Myers Squibb Co Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos totales | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 |
Ingresos | 19427 | 20776 | 22561 | 26145 | 42518 | 46385 |
Coste de los ingresos, total | 4925 | 5917 | 6436 | 7804 | 11133 | 9601 |
Beneficio bruto | 14502 | 14859 | 16125 | 18341 | 31385 | 36784 |
Gastos totales de explotación | 13480 | 15532 | 16175 | 19758 | 49365 | 37770 |
Gastos de venta/general/administración Gastos, total | 4911 | 4687 | 4550 | 4870 | 7733 | 7688 |
Investigación y desarrollo | 4927 | 4823 | 5052 | 5845 | 9519 | 9532 |
Depreciation / Amortization | 21 | 3 | 41 | 1206 | 9688 | 10023 |
Gastos (ingresos) extraordinarios | -585 | 1453 | 1449 | 1393 | 12819 | 2659 |
Other Operating Expenses, Total | -719 | -1351 | -1353 | -1360 | -1527 | -1733 |
Ingresos de explotación | 5947 | 5244 | 6386 | 6387 | -6847 | 8615 |
Ingresos por intereses (gastos), netos No operativos | 15 | 33 | -380 | -69 | -71 | -550 |
Otros, netos | -47 | -146 | -38 | -1343 | 47 | 33 |
Ingresos netos antes de impuestos | 5915 | 5131 | 5968 | 4975 | -6871 | 8098 |
Ingresos netos después de impuestos | 4507 | 3871 | 5003 | 3460 | -8995 | 7014 |
Intereses menores | -50 | 32 | -27 | -21 | -20 | -20 |
Beneficio neto antes de partidas extra. Elementos | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 |
Ingresos netos | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 4457 | 3903 | 4976 | 3439 | -9015 | 6994 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
Beneficio neto diluido | 4457 | 1007 | 4920 | 3439 | -9015 | 6994 |
Promedio ponderado de acciones diluidas | 1680 | 1652 | 1637 | 1712 | 2258 | 2245 |
BPA diluido sin partidas extraordinarias | 2.65298 | 2.36259 | 3.03971 | 2.00876 | -3.99247 | 3.11537 |
Dividends per Share - Common Stock Primary Issue | 1.52 | 1.56 | 1.6 | 1.64 | 1.8 | 1.96 |
BPA normalizado diluido | 2.38949 | 3.03729 | 3.78174 | 2.58034 | -0.19982 | 3.81069 |
Total de partidas extraordinarias | -2896 | -56 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Ingresos totales | 11073 | 11703 | 11624 | 11985 | 11648 |
Ingresos | 11073 | 11703 | 11624 | 11985 | 11648 |
Coste de los ingresos, total | 2503 | 2451 | 2291 | 2356 | 2471 |
Beneficio bruto | 8570 | 9252 | 9333 | 9629 | 9177 |
Gastos totales de explotación | 8812 | 9988 | 9628 | 9342 | 9095 |
Gastos de venta/general/administración Gastos, total | 1667 | 1882 | 1787 | 2352 | 1829 |
Investigación y desarrollo | 2225 | 2261 | 2440 | 2607 | 2220 |
Depreciation / Amortization | 2513 | 2547 | 2546 | 2417 | 2417 |
Gastos (ingresos) extraordinarios | 271 | 1252 | 989 | 146 | 635 |
Other Operating Expenses, Total | -367 | -405 | -425 | -536 | -477 |
Ingresos de explotación | 2261 | 1715 | 1996 | 2643 | 2553 |
Ingresos por intereses (gastos), netos No operativos | 257 | -170 | 149 | -786 | -960 |
Otros, netos | 12 | 8 | 12 | 1 | 94 |
Ingresos netos antes de impuestos | 2530 | 1553 | 2157 | 1858 | 1687 |
Ingresos netos después de impuestos | 2029 | 1061 | 1552 | 2372 | 1283 |
Intereses menores | -8 | -6 | -6 | 0 | -5 |
Beneficio neto antes de partidas extra. Elementos | 2021 | 1055 | 1546 | 2372 | 1278 |
Ingresos netos | 2021 | 1055 | 1546 | 2372 | 1278 |
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | 2021 | 1055 | 1546 | 2372 | 1278 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | 2021 | 1055 | 1546 | 2372 | 1278 |
Beneficio neto diluido | 2021 | 1055 | 1546 | 2372 | 1278 |
Promedio ponderado de acciones diluidas | 2265 | 2252 | 2243 | 2221 | 2164 |
BPA diluido sin partidas extraordinarias | 0.89227 | 0.46847 | 0.68926 | 1.06799 | 0.59057 |
Dividends per Share - Common Stock Primary Issue | 0.49 | 0.49 | 0.49 | 0.49 | 0.54 |
BPA normalizado diluido | 0.89007 | 0.85213 | 1.0486 | 1.02071 | 0.81817 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Activo Corriente | 13704 | 14854 | 17160 | 29354 | 30192 | 33262 |
Efectivo e inversiones a corto plazo | 6350 | 6812 | 8884 | 15393 | 15831 | 16966 |
Efectivo y Equivalentes | 4237 | 5421 | 6911 | 12346 | 14546 | 13979 |
Inversiones a corto plazo | 2113 | 1391 | 1973 | 3047 | 1285 | 2987 |
Total deudores, neto | 4916 | 5609 | 5747 | 7685 | 8501 | 9369 |
Accounts Receivable - Trade, Net | 3774 | 4347 | 4636 | 6476 | 7219 | 7979 |
Total Inventory | 1241 | 1166 | 1195 | 4293 | 2074 | 2095 |
Prepaid Expenses | 627 | 691 | 218 | 754 | 1799 | 2786 |
Other Current Assets, Total | 570 | 576 | 1116 | 1229 | 1987 | 2046 |
Total Assets | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 |
Property/Plant/Equipment, Total - Net | 4980 | 5001 | 5027 | 6956 | 6745 | 6968 |
Property/Plant/Equipment, Total - Gross | 9173 | 8987 | 8845 | 10911 | 10330 | 11001 |
Accumulated Depreciation, Total | -4193 | -3986 | -3818 | -3955 | -3585 | -4033 |
Goodwill, Net | 6875 | 6863 | 6538 | 22488 | 20547 | 20502 |
Intangibles, Net | 1385 | 1210 | 1091 | 63969 | 53243 | 42527 |
Long Term Investments | 2719 | 2480 | 1775 | 4601 | 4509 | 2713 |
Other Long Term Assets, Total | 4044 | 3143 | 3395 | 2576 | 3245 | 3342 |
Total Current Liabilities | 8841 | 9563 | 10654 | 18304 | 19080 | 21868 |
Accounts Payable | 1664 | 2248 | 1892 | 2445 | 2713 | 2949 |
Accrued Expenses | 4587 | 5313 | 5687 | 8100 | 9582 | 10104 |
Notes Payable/Short Term Debt | 243 | 987 | 454 | 583 | 340 | 184 |
Current Port. of LT Debt/Capital Leases | 749 | 0 | 1249 | 2763 | 2000 | 4764 |
Other Current Liabilities, Total | 1598 | 1015 | 1372 | 4413 | 4445 | 3867 |
Total Liabilities | 17530 | 21810 | 20955 | 78346 | 80659 | 73368 |
Total Long Term Debt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 |
Long Term Debt | 5716 | 6975 | 5646 | 43387 | 48336 | 39605 |
Minority Interest | 170 | 106 | 96 | 100 | 60 | 60 |
Other Liabilities, Total | 2803 | 5166 | 4559 | 10101 | 7776 | 7334 |
Total Equity | 16177 | 11741 | 14031 | 51598 | 37822 | 35946 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 221 | 221 | 221 | 292 | 292 | 292 |
Additional Paid-In Capital | 1725 | 1898 | 2081 | 43709 | 44325 | 44361 |
Retained Earnings (Accumulated Deficit) | 33513 | 31160 | 34065 | 34474 | 21281 | 23820 |
Treasury Stock - Common | -16779 | -19249 | -19574 | -25357 | -26237 | -31259 |
Unrealized Gain (Loss) | -7 | 32 | -30 | 6 | 11 | 2 |
Other Equity, Total | -2496 | -2321 | -2732 | -1526 | -1850 | -1270 |
Total Liabilities & Shareholders’ Equity | 33707 | 33551 | 34986 | 129944 | 118481 | 109314 |
Total Common Shares Outstanding | 1664 | 1625 | 1624 | 2228 | 2221 | 2153 |
Total Preferred Shares Outstanding | 0.00413 | 0.00407 | ||||
Deferred Income Tax | 6454 | 5407 | 4501 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 27111 | 29161 | 31443 | 33262 | 30121 |
Efectivo e inversiones a corto plazo | 12930 | 14016 | 15823 | 16966 | 14968 |
Efectivo y Equivalentes | 10982 | 11024 | 13540 | 13979 | 12369 |
Inversiones a corto plazo | 1948 | 2992 | 2283 | 2987 | 2599 |
Total deudores, neto | 8660 | 11275 | 11738 | 9369 | 8511 |
Accounts Receivable - Trade, Net | 7187 | 7713 | 7878 | 7979 | 7156 |
Total Inventory | 1953 | 2137 | 2163 | 2095 | 2104 |
Other Current Assets, Total | 3568 | 1733 | 1719 | 2046 | 4538 |
Total Assets | 112435 | 110797 | 110893 | 109314 | 103034 |
Property/Plant/Equipment, Total - Net | 6613 | 6801 | 6835 | 6968 | 6941 |
Property/Plant/Equipment, Total - Gross | 10243 | 10639 | 10805 | 11001 | 11109 |
Accumulated Depreciation, Total | -3630 | -3838 | -3970 | -4033 | -4168 |
Goodwill, Net | 20524 | 20529 | 20519 | 20502 | 20500 |
Intangibles, Net | 50819 | 48065 | 44930 | 42527 | 40103 |
Long Term Investments | 4636 | 3765 | 4784 | 2713 | 2185 |
Other Long Term Assets, Total | 2732 | 2476 | 2382 | 3342 | 3184 |
Total Current Liabilities | 17330 | 18991 | 21460 | 21868 | 22821 |
Accounts Payable | 2972 | 3609 | 2695 | 2949 | 2944 |
Accrued Expenses | 8491 | 8962 | 9971 | 10104 | 8319 |
Notes Payable/Short Term Debt | 277 | 158 | 296 | 184 | 225 |
Current Port. of LT Debt/Capital Leases | 1500 | 2497 | 4769 | 4764 | 7297 |
Other Current Liabilities, Total | 4090 | 3765 | 3729 | 3867 | 4036 |
Total Liabilities | 74830 | 73989 | 73680 | 73368 | 71454 |
Total Long Term Debt | 44505 | 42503 | 39677 | 39605 | 37450 |
Long Term Debt | 44505 | 42503 | 39677 | 39605 | 37450 |
Deferred Income Tax | 5235 | 4931 | 4956 | 4501 | 3809 |
Minority Interest | 68 | 66 | 71 | 60 | 65 |
Other Liabilities, Total | 7692 | 7498 | 7516 | 7334 | 7309 |
Total Equity | 37605 | 36808 | 37213 | 35946 | 31580 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 292 | 292 | 292 | 292 | 292 |
Additional Paid-In Capital | 43852 | 44064 | 44292 | 44361 | 43756 |
Retained Earnings (Accumulated Deficit) | 22204 | 22168 | 22625 | 23820 | 23948 |
Treasury Stock - Common | -27199 | -28198 | -28572 | -31259 | -35187 |
Unrealized Gain (Loss) | 9 | 7 | 4 | 2 | 1 |
Other Equity, Total | -1553 | -1525 | -1428 | -1270 | -1230 |
Total Liabilities & Shareholders’ Equity | 112435 | 110797 | 110893 | 109314 | 103034 |
Total Common Shares Outstanding | 2232.84 | 2222.11 | 2219.65 | 2153 | 2129.06 |
Prepaid Expenses | 2786 |
- Anual
- Trimestral
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Ingresos netos/Línea de salida | 4507 | 975 | 4947 | 3460 | -8995 | 7014 |
Efectivo de actividades de explotación | 3058 | 5275 | 5940 | 8067 | 14052 | 16207 |
Efectivo de actividades de explotación | 382 | 789 | 637 | 1746 | 10380 | 10686 |
Deferred Taxes | -204 | 1010 | 86 | -924 | 983 | -1393 |
Partidas no monetarias | -475 | 913 | 94 | 720 | 10701 | 1153 |
Cash Taxes Paid | 2000 | 546 | 747 | 1503 | 3400 | 3500 |
Intereses pagados en efectivo | 191 | 215 | 212 | 414 | 1600 | 1500 |
Cambios en el capital circulante | -1152 | 1588 | 176 | 3065 | 983 | -1253 |
Efectivo de actividades de inversión | 1480 | -66 | -874 | -9770 | -10859 | -538 |
Gastos de capital | -1215 | -1055 | -951 | -836 | -753 | -973 |
Otras partidas de flujo de caja de inversión, total | 2695 | 989 | 77 | -8934 | -10106 | 435 |
Efectivo procedente de actividades de financiación | -2653 | -4077 | -3535 | 7621 | -1151 | -16224 |
Elementos de flujo de caja de financiación | 15 | -22 | -54 | -53 | 542 | 641 |
Total Cash Dividends Paid | -2547 | -2577 | -2613 | -2679 | -4075 | -4396 |
Emisión (retiro) de acciones, neto | -231 | -2469 | -320 | -7300 | -1546 | -6287 |
Emisión (amortización) de deuda, neta | 110 | 991 | -548 | 17653 | 3928 | -6182 |
Efectos del cambio de divisas | -33 | 52 | -41 | -9 | 111 | -102 |
Variación neta de la tesorería | 1852 | 1184 | 1490 | 5909 | 2153 | -657 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 2029 | 3090 | 4642 | 7014 | 1283 |
Cash From Operating Activities | 3824 | 6884 | 12150 | 16207 | 3812 |
Cash From Operating Activities | 2668 | 5380 | 8107 | 10686 | 2584 |
Deferred Taxes | 68 | -95 | -127 | -1393 | -687 |
Non-Cash Items | -507 | 356 | 725 | 1153 | 994 |
Changes in Working Capital | -434 | -1847 | -1197 | -1253 | -362 |
Cash From Investing Activities | -143 | 37 | -939 | -538 | 95 |
Capital Expenditures | -173 | -383 | -653 | -973 | -253 |
Other Investing Cash Flow Items, Total | 30 | 420 | -286 | 435 | 348 |
Cash From Financing Activities | -7295 | -10477 | -12257 | -16224 | -5653 |
Financing Cash Flow Items | 172 | 448 | 644 | 641 | 333 |
Total Cash Dividends Paid | -1108 | -2207 | -3297 | -4396 | -1185 |
Issuance (Retirement) of Stock, Net | -1775 | -3011 | -3536 | -6287 | -5000 |
Issuance (Retirement) of Debt, Net | -4584 | -5707 | -6068 | -6182 | 199 |
Foreign Exchange Effects | -38 | -20 | -48 | -102 | 9 |
Net Change in Cash | -3652 | -3576 | -1094 | -657 | -1737 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.3545 | 198890804 | 3066015 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.2989 | 112662905 | 2240471 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.3424 | 92325898 | -602471 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 3.0052 | 63894939 | 526421 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 2.9555 | 62838772 | -1753198 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 2.4644 | 52396432 | 14298520 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8412 | 39147135 | 1131303 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.5702 | 33385956 | -2374239 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 1.0777 | 22914303 | 1075724 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.0666 | 22677818 | -372517 | 2021-12-31 | LOW |
Managed Account Advisors LLC | Investment Advisor | 1.0476 | 22273448 | -2068389 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 1.0412 | 22137675 | -74030 | 2022-09-30 | LOW |
Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 0.9424 | 20037642 | -147066 | 2022-09-30 | LOW |
Dodge & Cox | Investment Advisor/Hedge Fund | 0.789 | 16775562 | -1577777 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.7761 | 16501572 | -551586 | 2022-09-30 | LOW |
Nuveen LLC | Pension Fund | 0.7673 | 16313175 | 698391 | 2022-09-30 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7056 | 15001848 | -146955 | 2022-09-30 | LOW |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.6895 | 14659982 | 155845 | 2022-09-30 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.6759 | 14370082 | -23245 | 2022-09-30 | LOW |
Morgan Stanley Smith Barney LLC | Investment Advisor | 0.6643 | 14124064 | -3100460 | 2022-09-30 | LOW |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com GroupTraders
Clientes activos mensualmente
Volumen mensual de inversión
Retiros por mes
Calculadora de trading
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Bristol-Myers Squibb Company profile
Sobre Bristol-Myers Squibb Co
Bristol-Myers Squibb Company se dedica al descubrimiento, desarrollo, licenciamiento, fabricación, comercialización, distribución y venta de productos biofarmacéuticos. Los productos farmacéuticos de la compañía incluyen drogas sintetizadas químicamente, o moléculas pequeñas, y productos producidos a partir de procesos biológicos. Los medicamentos de molécula pequeña se administran por vía oral en forma de píldora o tableta. Los productos biológicos se administran a los pacientes mediante inyecciones o por infusión. Los productos de la compañía incluyen Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Franquicia de Hepatitis C, Franquicia Reyataz y Franquicia Sustiva. Ofrece productos para una amplia gama de clases terapéuticas, que incluyen virología, incluida la infección por el virus de la inmunodeficiencia humana (VIH); oncología; inmunosciencia y cardiovascular. Sus productos se venden a mayoristas, farmacias minoristas, hospitales, entidades gubernamentales y la profesión médica en todo el mundo.
- IndustriaPharmaceuticals (NEC)
- Dirección430 E 29th St Fl 14, NEW YORK, NY, United States (USA)
- Empleados32200
- CEOGiovanni Caforio
Industry: | Pharmaceuticals (NEC) |
430 E. 29Th Street
14 Floor
NEW YORK
NEW YORK 10016
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 485.000 traders de todo el mundo que eligen operar con Capital.com